XBiotech Inc. (XBIT:NASDAQ) closed at $2.12 on October 16, 2026, down 1.85% on the day. The stock trades 38.4% below its 52-week high of $3.44 and 1.4% above its 52-week low of $2.09. Over the past year, it lost 14.9%. XBiotech Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -7.42% | -2.75% | -5.78% | -15.54% | -14.86% |
In 252 trading sessions since October 16, 2025, XBIT closed higher on 95 days (38%). Its best day was November 11, 2025 (+20.00%) and its worst was November 19, 2025 (-8.09%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Find more stocks like XBIT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.